S

SimonMed

Outpatient imaging centers with AI diagnostics

PI Sales Manager

Full-Time
No salary listed
Mid
Scottsdale, AZ, USA
In Person
Sales & Account ManagementField Sales

About the job

Requirements
  • Experience in personal injury law, personal injury protection, and lien/letter of protection knowledge are preferred.
  • Demonstrate competency in job-related skills appropriate to the customer populations and departmental services.
  • Be able to plan and accomplish goals using experience and judgment.
  • Meet and exceed quarterly sales goals in the assigned territory.
  • Provide excellent customer service and demonstrate competency in job-related skills appropriate to customer populations and departmental services.
  • Utilize and operate equipment and mechanical devices that support a functional, effective, and safe environment.
  • Adhere to policies, procedures, and guidelines related to departmental operations.
  • The position may require lifting and carrying up to 40 pounds, sitting for prolonged periods, and frequent standing and walking.
  • Wear business casual attire.
  • Successful completion of drug and background screening is required for employment.
  • Some positions require a favorable driving record.
Responsibilities
  • Manage a team of sales representatives and develop their skills to attain revenue objectives.
  • Work closely with Regional Sales and Operations Directors to grow the market and ensure patient and provider satisfaction.
  • Work with sales leadership to develop and implement a strategic marketing plan for the assigned region.
  • Coach and develop direct reports, manage day-to-day performance of sales team members, and deliver reviews.
  • Monitor changes in the marketing environment and adjust plans to support organizational objectives.
  • Ensure correct usage of the customer relationship management system and other sales applications.
  • Track sales team metrics and regularly report data to leadership.
  • Report to the National PI Sales Director.
  • Perform other duties as assigned.
Desired Qualifications
  • Knowledge of personal injury law (tort law), personal injury protection, and lien/letter of protection practices.

About the company

S

SimonMed

View
Website

SimonMed is an outpatient medical imaging provider with about 170 imaging centers across 11 states, employing hundreds of subspecialty radiologists to interpret scans for referring physicians. It offers a full range of diagnostic services, including 3T MRI, CT, PET/CT, 3-D mammography, ultrasound, and X-ray, delivered through an integrated model that runs imaging centers and employs radiologists. The company uses AI to improve diagnostic accuracy in areas such as early breast cancer detection and cardiovascular imaging, and operates simonONE for personalized imaging diagnostics. Its goal is to provide high-quality imaging services at affordable prices, expanding access to early disease detection relative to hospital-based imaging.

Company Size

1,001-5,000

Company Stage

Acquired

Total Funding

$600M

Headquarters

Scottsdale, Arizona

Founded

2003

Get referred to SimonMed

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 2026 Cardiovascular Longevity opens new cash-pay screening revenue in California.
  • June 2026 Simplify Genomics partnership expands preventive imaging into genomics-enabled diagnostics.
  • Optellum and AIRS deals deepen AI moat, improving throughput, detection, and referral stickiness.

What critics are saying

  • January 2026 Arizona AG settlement exposed billing practices and mandates five-year reporting.
  • 2025 Medusa breach hit 1.275 million patients, driving class-action litigation and trust damage.
  • Whole-body MRI consumer diagnostics face reimbursement pressure; elective demand can collapse without celebrity-driven marketing.

What makes SimonMed unique

  • Nationwide scale: 175 centers across 10 states and 300 radiologists, June 2026.
  • April 2026 SwiftMR deployment standardized MRI quality across SimonMed's entire network.
  • SimonMed launched enterprise AI workflows for lung nodules, endometriosis, and cardiovascular screening.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Pet Insurance
  • Paid Holidays
  • PTO
  • Sick Time

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
VoM News
Oct 1st, 2026
SimonMed brings Arizona's first ai-powered Pristina Recon DL mammography technology to Scottsdale.

SimonMed brings Arizona's first ai-powered Pristina Recon DL mammography technology to Scottsdale. Advanced AI-powered software enhances 3D mammography image clarity to support early breast cancer detection at no additional cost to patients SCOTTSDALE, Ariz., October 1, 2026 - SimonMed, a leading company in radiology, imaging and longevity technology, today announced that it will become the first imaging provider in Arizona to introduce Pristina Recon DL, GE HealthCare's advanced AI-powered mammography image reconstruction technology. The software will be integrated into GE HealthCare's Senographe Pristina mammography system at SimonMed's Scottsdale Mountain View location, with the first patient examinations anticipated in early October, coinciding with Breast Cancer Awareness Month. Pristina Recon DL uses two deep learning models to enhance image quality and improve the visualization of subtle details that may be important in identifying breast cancer. The technology delivers sharp, clear 3D mammography images without increasing radiation dose or changing the patient exam experience. For patients, this means access to advanced imaging technology designed to provide greater diagnostic clarity while maintaining a comfortable, efficient screening experience. Regular screening lowers a woman's risk of dying from breast cancer by 26%, and when breast cancer is caught while still localized, the five-year survival rate climbs to 99%* - underscoring why sharp, clear imaging at the point of screening matters so much. "Early detection saves lives, and our mission at SimonMed is to bring the most advanced, life-saving technology to the communities we serve without creating additional financial barriers for patients," said John Simon, MD, Founder and Chief Executive Officer of SimonMed. "By bringing this technology to Arizona first, we're giving our radiologists even clearer images to help identify subtle signs of breast cancer and providing referring physicians with the advanced imaging they rely on to care for their patients. And we're making these advances available at no additional cost. That's what innovation should look like in healthcare." In a GE HealthCare preference study, radiologists preferred the overall image quality of Pristina Recon DL in 99.11% of image evaluations compared to previous digital breast tomosynthesis (DBT) reconstruction. Pristina Recon DL shows superior performance in the detection of microcalcification clusters and masses in a trial with modeled clinical data.** For referring providers, the technology represents another advancement in the imaging and diagnostic expertise available to their patients. By providing radiologists with sharp, clear 3D mammography images, SimonMed aims to support the identification and evaluation of subtle findings, helping physicians make informed decisions about patient care and recommended next steps. "At GE HealthCare, we're focused on developing innovations that give clinicians the clarity and confidence they need to deliver exceptional patient care," said Victoria Daly, VP, Women's Health, US and Canada, GE HealthCare. "By implementing Pristina Recon DL, SimonMed is bringing advancements in deep learning image reconstruction to women in Arizona, combining exceptional image quality with an efficient, patient-centered mammography experience. Together, we're helping expand access to innovative solutions that can help support early detection of breast cancer."

Smart Business News
Aug 25th, 2026
SimonMed launches world's first enterprise-scale integrated AI lung nodule risk assessment workflow.

SimonMed launches world's first enterprise-scale integrated AI lung nodule risk assessment workflow. Multiple FDA-cleared AI technologies are integrated into a single clinical workflow for lung nodule detection, characterization and malignancy-risk prediction - without disrupting how radiologists work. SCOTTSDALE, AZ - Aug 25- SimonMed, one of the largest outpatient medical imaging providers and radiology practices in the United States, announced a partnership with Optellum, an AI-powered lung cancer diagnostics company, to integrate advanced lung nodule risk-stratification AI directly into its existing AI-enabled clinical workflow. This integration is designed to give referring providers an objective, validated assessment of malignancy risk for eligible incidentally detected pulmonary nodules, supporting earlier and more appropriate patient care. Under this new partnership, eligible lung nodules identified during standard chest CT scans will flow into Optellum's Lung Cancer Prediction (LCP) AI for evaluation. Optellum's software is the first AI-based decision-support tool cleared by the FDA for malignancy risk prediction of eligible incidentally detected pulmonary nodules. The software analyzes various nodule characteristics and generates a validated AI-derived Lung Cancer Prediction (LCP) score to assist in informing clinical decision-making. "For the first time, eligible pulmonary nodules can move seamlessly from detection to malignancy risk assessment without requiring a separate workflow, additional clicks, or manual case selection," said Dr. Sean Raj, Chief Medical Officer and Chief Innovation Officer at SimonMed. "We believe this represents the world's first enterprise-wide deployment of an integrated AI-powered pathway for lung nodule detection, characterization, and malignancy risk prediction. It's a major step toward ensuring every patient with a potentially dangerous lung nodule receives a consistent, objective assessment, while keeping the radiologist firmly at the center of clinical decision-making." Millions of lung nodules are found incidentally on CT scans each year, but timely and appropriate follow-up remains a challenge. Traditional risk models can leave clinicians uncertain, leading to delayed diagnoses of malignant nodules or unnecessary procedures for benign ones. By evaluating every eligible pulmonary nodule within the radiologist's existing workflow, SimonMed helps ensure consistent, AI-powered risk assessment across the enterprise while reducing variability and the chance that high-risk nodules are overlooked. The integration of Optellum LCP AI builds on SimonMed's existing AI-enhanced lung nodule program, powered by Infervision, which already provides automated volumetric sizing and interval-growth tracking. By adding Optellum's risk prediction technology, SimonMed gives referring providers clearer guidance while continuing to advance a more targeted, imaging-based assessment of pulmonary nodules. "We are thrilled to partner with SimonMed to bring our LCP AI to their extensive network of clinics," said Dr. Johnathan Watkins, CEO of Optellum. "SimonMed's commitment to making cutting-edge diagnostic technology accessible aligns with our mission to ensure no lung nodule is left behind. By risk-stratifying patients at the point of diagnosis, we can help their subspecialty radiologists and referring clinicians prioritize the right patients for life-saving interventions. And with Optellum's LCP AI uniquely named in Medicare payment policy and reimbursed by commercial payers, partnerships like this can scale sustainably, bringing earlier diagnosis to more patients." While the workflow is designed for speed and ease of use, specialist oversight remains central. The Optellum LCP score serves as clinical decision support and is interpreted alongside imaging, prior exams, patient risk factors, and clinical guidelines. Every AI-generated risk score is reviewed and confirmed by a board-certified SimonMed radiologist before inclusion in the final report, ensuring referred providers receive trusted, actionable findings. Once fully deployed, this workflow will automatically evaluate pulmonary nodules across one of the nation's largest outpatient imaging networks, representing one of the largest enterprise implementations of AI-powered lung cancer risk assessment worldwide. The Optellum integration is the latest milestone in SimonMed's broader strategy to advance medical imaging through clinically validated AI. Across multiple imaging specialties, SimonMed continues to invest in technologies that enhance diagnostic accuracy, improve efficiency, and provide referring providers with more meaningful insights, while ensuring every result remains under the review and oversight of board-certified radiologists.

Smart Business News
Jul 29th, 2026
SimonMed launches Cardiovascular Longevity, transforming heart disease from a silent killer into a preventable condition.

SimonMed launches Cardiovascular Longevity, transforming heart disease from a silent killer into a preventable condition. PHOENIX, Ariz., July 29, 2026 - SimonMed, one of the largest outpatient medical imaging providers and radiology practices in the United States, on July 28 announced the launch of Cardiovascular Longevity, an integrated preventive cardiovascular health program designed to help people understand their health before symptoms develop. According to the World Health Organization, cardiovascular disease is the leading cause of death worldwide, claiming an estimated 19.8 million lives each year, or approximately 32% of all global deaths. In the United States, cardiovascular disease remains the leading cause of death, claiming more lives each year than all forms of cancer combined. SimonMed is working to change that by expanding access to advanced cardiac screening designed to detect disease before symptoms appear with Cardiovascular Longevity. Cardiovascular Longevity combines advanced blood biomarkers, Coronary CT Angiography (CCTA) with AI-powered plaque analysis, and a one-on-one consultation with a preventive cardiologist into a single cardiovascular assessment designed to identify disease earlier and create a personalized prevention plan. Rather than relying solely on medical history, cholesterol tests and imperfect risk calculators, the program provides patients with a more complete understanding of what's happening inside their heart, what's driving their cardiovascular risk, and what they can do to reduce it. "For decades we've accepted that heart disease is something we discover after symptoms appear," said Dr. John Simon, Founder and CEO of SimonMed. "That model is no longer good enough. The technology now exists to identify cardiovascular disease much earlier, understand why it's developing, and intervene before it becomes life changing. Cardiovascular Longevity represents the future of preventive medicine, where advanced imaging, blood biomarkers, artificial intelligence, and specialist care come together to help patients protect their hearts rather than simply treat disease." Cardiovascular Longevity combines three complementary assessments: Advanced Blood Biomarkers A comprehensive cardiometabolic blood panel evaluates cholesterol particles, inflammation, blood sugar, Lipoprotein(a), and other biomarkers that help explain why cardiovascular disease develops. Coronary CT Angiography with AI Plaque Analysis A non-invasive CT scan allows physicians to see inside the coronary arteries, identifying both soft and calcified plaque before symptoms appear. Advanced AI analyzes the scan to measure plaque burden and provide deeper insight into cardiovascular risk. Consultation with a Preventive Cardiologist Following testing, patients meet virtually with Dr. Brandon Rafison, board-certified internist and cardiologist, and Medical Director of SimonMed Longevity, to review their results and receive a personalized prevention strategy. "Today, we can move beyond guesswork by using advanced imaging to directly visualize the heart and precisely measure atherosclerotic plaque," said Dr. Brandon Rafison, Medical Director of SimonMed Longevity. "This allows us to determine whether heart disease is actually present and make personalized recommendations based on each individual's unique risk, helping avoid both over- and undertreatment. By combining these advanced diagnostics with expert clinical interpretation, we're giving patients clear, actionable insights they can understand and use to take control of their health. Whether we confirm a healthy heart or detect disease early, before symptoms appear, we're empowering people with information that could prevent a future heart attack, heart failure or stroke. For many patients, that can be life-changing." Cardiovascular Longevity is part of SimonMed Longevity, a growing portfolio of preventive health programs designed to help patients detect disease earlier, better understand their health, and take action before symptoms appear. Currently, it is available to patients in California with a national rollout planned later this year.

VoM News
Jun 29th, 2026
Simplify Genomics and SimonMed announce collaboration to advance preventive healthcare through integrated genomics and imaging.

Simplify Genomics and SimonMed announce collaboration to advance preventive healthcare through integrated genomics and imaging. Simplify Genomics and SimonMed Announce Collaboration to Advance Preventive Healthcare Through Integrated Genomics and Imaging Combining whole genome interpretation with large-scale whole-body MRI to enable a more comprehensive view of human health. Discover more Public Finance South Asians & Diaspora Local News San Diego, CA - June 29, 2026 - Simplify Genomics today announced a collaboration with SimonMed aimed at advancing a more integrated approach to preventive healthcare. By combining SimonMed's national scale in whole-body MRI with Simplify's Whole Genome Interpretation and Reporting Platform, the collaboration seeks to provide a more complete picture of human health - helping identify risk earlier, personalize care pathways, and support more proactive health decisions. Across both imaging and genomics, there is growing evidence that early indicators associated with disease may be identified well before they surface in traditional care pathways. Together, these modalities offer complementary perspectives: genomics can provide insight into underlying disease risk, while imaging can help identify existing structural or physiological changes. Simplify Genomics has spent years developing and refining its clinical reporting platform as a CAP/CLIA-certified laboratory and has processed in excess of 50,000 whole genomes to date. The platform includes thousands of disease associations and a broad set of pharmacogenomic insights, designed to support clinical interpretation and integration within real-world care settings. Paired with SimonMed's leadership in accessible, AI-enhanced imaging at national scale - including a network of more than 175 imaging centers across the United States - the collaboration creates an opportunity to explore patterns and connections that may not be visible through any single modality alone, supporting earlier insight and helping to inform clinical decision-making. "This collaboration reflects a shared vision for the future of healthcare - one that is more proactive, data-driven, and personalized," said Travis Lacey, CEO of Simplify Genomics. "We believe the future of healthcare lies in making advanced preventive insights more accessible and actionable," said John Simon, CEO of SimonMed. "By combining imaging and genomics, we have an opportunity to help patients and providers better understand health risk earlier and with greater clarity." The collaboration is progressing rapidly, with additional updates expected in the near future. About Simplify Genomics Simplify Genomics is a CAP/CLIA-certified clinical laboratory focused on advancing the use of whole genome sequencing in healthcare. Spun out of Human Longevity in 2022, the company has developed a comprehensive Whole Genome Interpretation and Reporting Platform that integrates thousands of disease associations and pharmacogenomic insights to support clinical interpretation in real-world care settings. Simplify Genomics has processed more than 50,000 whole genomes and is committed to expanding access to high-quality genomic insights while enabling a more proactive, personalized approach to health. About SimonMed Headquartered in Scottsdale, Arizona, SimonMed is one of the largest outpatient diagnostic imaging and health technology providers in the United States. SimonMed operates more than 175 centers across 10 states and is supported by a nationwide team of more than 300 subspecialty-trained, board-certified radiologists. SimonMed provides the full spectrum of diagnostic imaging services from X-ray to complex Cardiac MRI and is a recognized leader in the clinical use of artificial intelligence. SimonMed Longevity is a division focused on proactive health. It offers whole-body MRI and preventive, multi-modality screening designed to help patients establish a baseline of their health, track changes over time, and identify potential risk earlier - when informed action may help prevent or delay disease. VoM News is an online web portal in jammu Kashmir offers regional, National & global news. Local News

Finnews Network
May 29th, 2026
4DMedical expands US presence with SimonMed Imaging partnership.

4DMedical expands US presence with SimonMed Imaging partnership. 4DMedical Limited (ASX:4DX), a global medical technology company revolutionising respiratory care with advanced imaging and artificial intelligence, today announced a significant commercial agreement. Its patented XV Technology(R) transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision. The Melbourne-based firm has secured a contract with SimonMed Imaging, one of the leading outpatient medical imaging providers in the United States, for the immediate deployment of its CT:VQ(TM) and LDAf(TM) advanced quantitative cardiopulmonary analysis solutions. This partnership extends 4DMedical's technology into SimonMed's extensive network of over 170 outpatient imaging centres across 10 U.S. states. Under the three-year agreement, SimonMed will integrate 4DMedical's CT:VQ(TM) and LDAf(TM) to enhance its existing CT imaging services. These solutions are designed to support improved clinical decision-making for pulmonary assessment by providing deeper, objective insights into regional lung function. The agreement features immediate clinical deployment on commercial terms from day one, with pricing based on 4DMedical's per-scan rates. SimonMed, recognised for its methodical approach to technology adoption, thoroughly validates new capabilities before large-scale deployment, lending significant credibility to this partnership. While the agreement is not immediately financially material, it represents a clear commercial win and a material long-term opportunity for 4DMedical. A crucial aspect of the collaboration involves SimonMed supporting the development of reimbursement evidence for CT:VQ(TM) across both public and private payors, including the sharing of insurance and claims data. This strategic partnership reinforces 4DMedical's position as a partner of choice for next-generation CT-based functional imaging in the U.S., leveraging its scalable Software-as-a-Service (SaaS) delivery model for efficient implementation across large multi-site networks.